Skip header and navigation
Did you mean name:" Sirpa leppã"? Also try leppã, or leppä.

Refine By

3 records – page 1 of 1.

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

https://arctichealth.org/en/permalink/ahliterature272653
Source
Leuk Lymphoma. 2015 Jul;56(7):2005-12
Publication Type
Article
Date
Jul-2015
Author
Karen Juul Mylam
Lale Kostakoglu
Martin Hutchings
Morton Coleman
Dominick Lamonica
Myron S Czuczman
Louis F Diehl
Anne L Nielsen
Paw Jensen
Annika Loft
Helle W Hendel
Victor Iyer
Sirpa Leppä
Sirkku Jyrkkiö
Harald Holte
Mikael Eriksson
Dorte Gillstrøm
Per B Hansen
Marko Seppänen
Karin Hjorthaug
Peter de Nully Brown
Lars M Pedersen
Source
Leuk Lymphoma. 2015 Jul;56(7):2005-12
Date
Jul-2015
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Denmark
Female
Finland
Fluorodeoxyglucose F18 - pharmacokinetics
Follow-Up Studies
Humans
Lymphoma, Large B-Cell, Diffuse - drug therapy - mortality - pathology
Male
Middle Aged
Multimodal Imaging
Neoplasm Staging
Norway
Positron-Emission Tomography - methods
Prognosis
Prospective Studies
Radiopharmaceuticals - pharmacokinetics
Survival Rate
Sweden
Tissue Distribution
Tomography, X-Ray Computed - methods
United States
Young Adult
Abstract
We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International Harmonization Project criteria (IHP), Deauville 5-point scale (D 5PS) with scores 1-3 considered negative (D 5PS > 3) and D 5PS with scores 1-4 considered negative (D 5PS = 5). Ratios of tumor maximum standardized uptake value (SUVmax) to liver SUVmax were also analyzed. We found no difference in progression-free survival (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS > 3. The 2-year PFS using D 5PS = 5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p = 0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups.
PubMed ID
25330442 View in PubMed
Less detail

Clinical findings of extranodal SNT lymphoid malignancies in a four-decade single-centre series.

https://arctichealth.org/en/permalink/ahliterature280856
Source
Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3839-3845
Publication Type
Article
Date
Nov-2016
Author
Pauli Vähämurto
Kaija Silventoinen
Seija I Vento
Marja-Liisa Karjalainen-Lindsberg
Aaro Haapaniemi
Leif Bäck
Susanna Mannisto
Sirpa Leppä
Antti A Mäkitie
Source
Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3839-3845
Date
Nov-2016
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Female
Finland - epidemiology
Humans
Incidence
Lymphoproliferative Disorders - epidemiology - pathology
Male
Middle Aged
Nose Neoplasms - epidemiology - pathology
Paranasal Sinus Neoplasms - epidemiology - pathology
Pharyngeal Neoplasms - epidemiology - pathology
Retrospective Studies
Abstract
Sinonasally located lymphoid malignancies are rare lesions with first symptoms similar to other obstructive conditions. Additionally, they often coexist with nasal inflammation and mucosal necrosis. Therefore, time from the first symptoms to diagnosis tends to be long. Awareness and early diagnosis of this disease entity could improve treatment outcome. Altogether, 142 patients with sinonasal or nasopharyngeal (i.e. sinonasal tract, SNT) lymphoid malignancies, diagnosed and treated at the Helsinki University Hospital, during a 39-year period from 1975 to 2013, were retrospectively reviewed. There were 90 males (63?%) and 52 females (37?%) with a median age of 64?years (range 26-92). Eighty-four percent of the patients had primary diseases and 16?% had relapses of lymphoid malignancies primarily diagnosed at other locations. The mean duration of symptoms prior to diagnosis was 4.8?months (range 0.5-24). The most common histological entity was diffuse large B-cell lymphoma (43?%), followed by plasmacytoma (18?%). The most common location was nasopharynx (58?%) followed by nasal cavity (44?%) and paranasal sinuses (35?%). Sixty-nine percent of the lesions were at a single anatomic location of the sinonasal tract. Fifty-two percent of the cases were of Ann Arbor Stage I. Lymphoid malignancies form an important and diverse group in the differential diagnosis of SNT tumours. They most often present with general obstructive nasal symptoms due to tumour location. Most of them are primary lesions, highlighting the importance of an accurate diagnosis as early as possible.
PubMed ID
27010643 View in PubMed
Less detail

Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.

https://arctichealth.org/en/permalink/ahliterature270036
Source
Acta Oncol. 2015 Jun;54(6):939-43
Publication Type
Article
Date
Jun-2015
Author
Liisa Harjama
Hanne Kuitunen
Taina Turpeenniemi-Hujanen
Kirsi Maria Haapasaari
Sirpa Leppä
Susanna Mannisto
Marja-Liisa Karjalainen-Lindsberg
Tuula Lehtinen
Mine Eray
Martine Vornanen
Hannu Haapasalo
Ylermi Soini
Esa Jantunen
Tapio Nousiainen
Kaija Vasala
Outi Kuittinen
Source
Acta Oncol. 2015 Jun;54(6):939-43
Date
Jun-2015
Language
English
Publication Type
Article
Keywords
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Brain Neoplasms - drug therapy
Cytarabine - administration & dosage
Disease-Free Survival
Female
Finland
Humans
Lymphoma - drug therapy
Male
Methotrexate - administration & dosage
Middle Aged
Recurrence
Retrospective Studies
Rituximab - administration & dosage
Survival Rate
Treatment Outcome
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare brain tumour with a dismal prognosis. Several phase II studies with high-dose methotrexate-based regimens have shown promising early results, but in all hospital-based data published so far, the disease outcome is poor.
We performed a hospital-based retrospective analysis to evaluate the long-term results of the Nordic type of Bonn chemotherapy regimen in PCNSL patients. The study included 54 patients with newly diagnosed PCNSL who received chemotherapy with curative intent as their first-line treatment.
We found promising response rates, 76% of the patients achieving CR and 22% patients achieving PR, with corresponding two-year EFS 53% and OS 76%. However, with longer follow-up a constant pattern of relapses was observed with only one patient remaining in primary remission after 60 months.
The finding suggests that basic biological differences exist between PCNSL and systemic diffuse large B-cell lymphoma and there is a need for consolidation or maintenance therapy after achieving a remission in patients with PCNSL.
PubMed ID
25761092 View in PubMed
Less detail